Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Bladder Cancer Biomarkers Aid in Diagnosis, Monitoring

November 5th 2016

When it comes to the burgeoning arena of biomarkers in bladder cancer, the value proposition is compelling, although the utility and costs need to be better defined, according to Badrinath Konety, MD, MBA.

Cabozantinib Benefits Similar in MET Expressing Advanced RCC

November 5th 2016

Cabozantinib demonstrated consistent benefits compared with everolimus for patients with advanced, pretreated renal cell carcinoma in a subgroup analysis of the phase III METEOR trial that explored MET expression.

Dr. Hutson on Lenvatinib/Everolimus Combo in RCC

November 5th 2016

Thomas E. Hutson, DO, PharmD, director of the Genitourinary Oncology Program, Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the efficacy associated with the combination of levantinib (Lenvima) and everolimus (Afinitor) in patients with metastatic renal cell carcinoma (RCC).

Dr. Haas on Adjuvant VEGF-Targeted Therapy in RCC

November 5th 2016

Naomi B. Haas, MD, director, Prostate and Kidney Cancer Program Associate Professor of Medicine at the Hospital of the University of Pennsylvania, discusses results of 2 ongoing clinical trials looking at adjuvant therapy options in renal cell carcinoma (RCC).

Expert Examines Conflicting Adjuvant RCC Results

November 5th 2016

Conflicting results from large adjuvant studies for renal cell carcinoma may have been caused by differences between the clinical trial designs, patient populations, and assessment criteria.

Dr. Plimack on Significance of CheckMate-025 Trial in RCC

November 5th 2016

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses updated findings from the CheckMate-025 trial, which compared the efficacy of nivolumab (Opdivo) with everolimus (Afinitor) in patients with renal cell carcinoma.

Dr. Geoffrey Sklar On Immunotherapy Advancements in Bladder Cancer

November 5th 2016

Dr. Geoffrey Sklar, Chief Medical Officer, Chesapeake Urology Associates, spoke with OncLive about some of the exciting advancements in bladder cancer during the LUGPA Annual Meeting.

Expert Discusses Neoadjuvant Treatment Potential in Advanced RCC

November 5th 2016

Neoadjuvant therapy is evolving as a treatment approach for patients with advanced renal cell carcinoma.

Novel Targeted Agents in Development, But Will Compete With Immunotherapy in RCC

November 5th 2016

Toni K. Choueiri, MD, dives into the ongoing research with volitinib, the competing yet complementary roles of targeted agents and immunotherapy, and the most important steps to take with biomarker research in the field of renal cell carcinoma.

Dr. Cost on Pembrolizumab Plus Axitinib in Patients With RCC

November 5th 2016

Nicholas G. Cost, MD, assistant professor, Surgery-Urology, Department of Pediatric Urology/ Urologic Oncology, University of Colorado Denver, discusses a clinical trial exploring pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with renal cell carcinoma (RCC).

Urology Expert Speaks on Key Advancements, PSA Testing in Prostate Cancer

November 5th 2016

The life expectancy of patients with metastatic castrate-resistant prostate cancer has doubled in recent years thanks to a multitude of new therapies, and there are still many more advancements to come.

Dr. Mohammed Haseebuddin on Expanding Role for Immunotherapy in RCC

November 3rd 2016

Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discuses why continued research into immunotherapy in clear cell renal cell carcinoma (RCC) is important, particularly in the adjuvant and neoadjuvant settings.

Dr. Pal on Sequencing Challenges for the Treatment of Patients With RCC

November 3rd 2016

Sumanta Kumar Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the challenges with sequencing the therapies available for patients with renal cell carcinoma (RCC). Pal shared this insight in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

Expert Discusses Promise of Nivolumab in Advanced Bladder Cancer

November 1st 2016

Results from the phase II CheckMate-275 trial demonstrated favorable safety and efficacy with the PD-1 inhibitor nivolumab as a second-line treatment for patients with metastatic urothelial cancer who have progressed on first-line chemotherapy.

First-Line Pembrolizumab Just the Beginning for Novel Approaches in Bladder Cancer

October 27th 2016

First-line pembrolizumab demonstrated significant antitumor activity in cisplatin-ineligible patients with metastatic urothelial cancer.

Novel Agents, Combinations Advance Second-Line RCC Care

October 27th 2016

The treatment paradigm of advanced renal cell carcinoma (RCC) has been rapidly changing. First, the FDA approved the combination of lenvatinib and everolimus in May 2016 as a treatment for patients with advanced RCC following prior antiangiogenic therapy.

Dr. David Nanus on Atezolizumab for Urothelial Bladder Cancer

October 22nd 2016

David Nanus, MD, medical oncologist, Weill Cornell Medicine, discusses the impact of atezolizumab for patients with advanced urothelial bladder cancer.

FDA Grants Nivolumab Priority Review for Urothelial Carcinoma

October 22nd 2016

The FDA has granted a priority review designation to nivolumab as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy.

Pembrolizumab Improves Survival in Pretreated Bladder Cancer

October 21st 2016

Pembrolizumab improved survival compared with chemotherapy in previously treated patients with advanced urothelial cancer in the phase III KEYNOTE-045 trial.

Dr. Choueiri on Ongoing Trials of Immunotherapy in RCC

October 20th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses some of the ongoing trials evaluating different immunotherapy agents in renal cell carcinoma.